1.Optimal dose of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease.
Dae Won KIM ; Eun Suk KANG ; Hyun Suk CHI ; Won Ki MIN ; Chowl Won SUH
Korean Journal of Blood Transfusion 1993;4(1):67-74
No abstract available.
Graft vs Host Disease*
2.Chronic Cutaneous Graft versus Host Disease Mimicking Warts.
Bo In LEE ; Young Min PARK ; Hyung Ok KIM ; Jun Young LEE
Annals of Dermatology 2015;27(1):90-92
No abstract available.
Graft vs Host Disease*
;
Warts*
3.Acute Graft-versus-Host Disease after Liver Transplantation.
Hyunju JIN ; Hyunho CHO ; Wonjeong KIM ; Jeho MUN ; Margaret SONG ; Hoon Soo KIM ; Byung Soo KIM ; Moon Bum KIM ; Hyun Chang KO
Korean Journal of Dermatology 2014;52(10):761-763
No abstract available.
Graft vs Host Disease*
;
Liver Transplantation*
4.Graft-versus-Host Disease: Report of Four Cases.
Jong Yuk YI ; Baik Kee CHO ; Won HOUH ; Chong Won PARK ; Choon Choo KIM
Annals of Dermatology 1989;1(1):21-27
No abstract available.
Graft vs Host Disease*
;
HLA-DR Antigens
6.Acute Cutaneous Graft-Versus-Host Reaction.
Annals of Dermatology 1997;9(2):77-86
Graft-versus-host disease occurs after the administration of foreign immunologically competent cells to an individual who is immunologically compromised. It is a clinical syndrome characterized by cutaneous changes, gastrointestinal dysfunction and liver dysfunction. Cutaneous graft-versus-host reaction is usually the earliest and certainly the most common form of the disease. The diagnosis of graft-versus-host disease is a complex clinicopathologic skill requiring considerable experience. There as yet appears to be no pathognomonic single clinical or histologic feature in the acute phase. In this review article, the definition, immunological aspects and. clinical features of graft-versus-host disease, diagnostic criteria of acute cutaneous graft-versus-host reaction and graft-versus-tumor effect are discussed.
Diagnosis
;
Graft vs Host Disease
;
Liver Diseases
7.The role of B cells in acute graft-versus-host disease.
Byung Sik CHO ; Nak Gyun CHUNG
Korean Journal of Hematology 2011;46(4):287-288
No abstract available.
B-Lymphocytes
;
Graft vs Host Disease
8.Subacute Radiation Dermatitis due to Fluoroscopy during Cardiac Intervention.
June Ho WON ; Sook Jung YUN ; Jee Bum LEE ; Seong Jin KIM ; Seung Chul LEE ; Young Ho WON
Korean Journal of Dermatology 2010;48(10):866-868
Subacute radiation dermatitis is a cutaneous disorder that occurs secondary to radiation exposure. It occurs after weeks to a few months from radiation exposure. Histologically, subacute radiation dermatitis presents with interface dermatitis that resembles graft-versus-host disease or a fixed drug eruption. The previous reports on this disease have usually been related to extensive or repeated coronary angiography. Herein, we report on a case of subacute radiation dermatitis that occurred 5 weeks after cardiac intervention therapy.
Coronary Angiography
;
Dermatitis
;
Drug Eruptions
;
Fluoroscopy
;
Graft vs Host Disease
9.New Strategies for Overcoming Limitations of Mesenchymal Stem Cell-Based Immune Modulation.
International Journal of Stem Cells 2015;8(1):54-68
Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual efficacy of MSCs in various diseases has evoked a sense of discouragement. Therefore, we believe that MSC therapy may now be at a critical milestone for re-evaluation and re-consideration. In this review, we summarize the current status of MSC-based clinical trials and focus on the discrepancy between expected and actual outcome of MSC therapy from bench to bedside. Importantly, we discuss the underlying limitations of MSCs and suggest a new guideline for MSC therapy in hopes of improving their therapeutic efficacy.
Graft vs Host Disease
;
Hope
;
Mesenchymal Stromal Cells
10.Therapeutic Effects of 0.03% Tacrolimus Eye Drops for Chronic Ocular Graft-Versus-Host Disease.
Journal of the Korean Ophthalmological Society 2015;56(10):1505-1510
PURPOSE: To evaluate the therapeutic effects of 0.03% tacrolimus eye drops on dry eye associated with chronic ocular graft-versus-host disease (GVHD). METHODS: This study included 24 eyes of 12 patients with refractory dry eye associated with chronic ocular GVHD who were unresponsive to topical steroid and 0.05% topical cyclosporine. The topical steroid and cyclosporine were discontinued for 2 weeks before treatment and 0.03% tacrolimus eye drops were applied twice a day for 1 month. Artificial tears, ointment, and lid cleanser were used in the same manner before initiating tacrolimus treatment. Ocular staining score, tear break-up time, ocular surface disease index (OSDI), and Schirmer I test score were evaluated. RESULTS: Ocular staining score, tear break-up time, and OSDI improved with statistical significance (p < 0.05) after 28 days of treatment. Schirmer I test did not show statistical improvement after treatment. CONCLUSIONS: The use of 0.03% tacrolimus eye drops were effective for refractory dry eye associated with chronic ocular GVHD.
Cyclosporine
;
Graft vs Host Disease*
;
Humans
;
Ophthalmic Solutions*
;
Tacrolimus*
;
Tears